FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Top Cited Papers
Open Access
- 1 September 2015
- journal article
- Published by Elsevier BV in Cancer Cell
- Vol. 28 (3), 285-295
- https://doi.org/10.1016/j.ccell.2015.08.004
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?Science, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagementProceedings of the National Academy of Sciences of the United States of America, 2012
- Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 AntibodiesScience, 2011
- FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivoProceedings of the National Academy of Sciences of the United States of America, 2010
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009